Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis

Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Morten A Karsdal, Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Morten A Karsdal

Abstract

Background: Excessive cartilage degradation is a known characteristic of osteoarthritis (OA). Biochemical markers, such as uCTX-II, have been shown to be associated with disease severity, yet the tissue origin of CTX-II has been disputed. This analysis investigates the association between OA knee joints at different radiographic stages and pain categories with levels of uCTX-II and biomarkers of bone resorption and formation.

Methods: Baseline data of two randomised clinical trials (NCT00486434 and NCT00704847) in patients with radiographic OA and presence of pain were analysed post hoc. A subgroup with available urine samples and evaluable radiographs for both knees (N = 1241) was analysed. Urine CTX-I, urine CTX-II and serum osteocalcin were analysed for associations with combined Kellgren-Lawrence (KL) scores, gender and pain for both knees to assess the contribution of joints at different stages.

Results: Pain, BMI, age, gender and KL grade were all significantly associated with uCTX-II. The association between pain and CTX-II appeared to be driven by weight-bearing pain. The level of uCTX-II incrementally increased with higher radiographic severity of each knee. Levels of bone markers CTX-I and osteocalcin were both significantly associated with BMI and gender, but neither were associated with radiographic severity. Biomarker levels between male or female groups of identical KL scores were found to be higher in females compared to males in some but not all KL score groups.

Conclusions: These results indicate that levels of uCTX-II are independently associated with radiographic severity of OA and pain intensity. CTX-II was associated with weight-bearing pain, but not non-weight-bearing pain, independent of co-variates. Bilateral OA knee joints appear to contribute to uCTX-II levels in an incremental manner according to radiographic severity of single joints. The data suggest that biomarker differences between genders should be taken into account when evaluating these markers in the context of structural features of OA.

Keywords: Biomarkers; Bone; Cartilage; Osteoarthritis; Pain; Radiography.

Conflict of interest statement

ARB, IB, ACBJ, CC, BJR, JRA and MAK are full-time employees in Nordic Bioscience, a company engaged in biomarker research and development of treatments for osteoarthritis. The ELISA assays for uCTX-I, uCTX-II and N-MID osteocalcin were developed by Nordic Bioscience but were acquired by Immunodiagnostic Systems UK as Urine Beta Crosslaps®, Urine Cartilaps® and N-MID® Osteocalcin respectively in 2007. ARB, ACBJ, CC, BJR, JRA and MK are shareholders of Nordic Bioscience. BJR and CC are major shareholders and board members of Nordic Bioscience.

Figures

Fig. 1
Fig. 1
Association between Kellgren-Lawrence and biomarkers of bone and cartilage turnover. Association between geometric mean concentration of uCTX-II (creatinine corrected) (Fig. 1a-c), uCTX-I (creatinine corrected) (Fig. 1d-f) and serum osteocalcin (Fig. 1g-i)
Fig. 2
Fig. 2
Association between WOMAC pain and the CTX-II biomarker of cartilage turnover. Association between geometric mean concentration of uCTX-II (creatinine corrected) and pain intensity in the full study population (N = 1241) and by gender (male: N = 399, female: N = 842). Groups of pain intensity consist of tertiles of WOMAC pain sub-score intensity of each knee (ranging from 0 to 100), resulting in six groups ranging from mild pain in both knees (“Low-Low”) to severe pain (“High-High”) in both knees. Error bars represent ± 1sem range. “a” p < 0.05 compared to the “Low-Low” group. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

References

    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(1474–547X (eElectronic)):2163–2196. doi: 10.1016/S0140-6736(12)61729-2.
    1. Buckwalter JA, Mankin HJ, Grodzinsky AJ. Articular cartilage and osteoarthristis. AAOS Instr Course Lect. 2005;54:465–480.
    1. Taljanovic MS, Graham AR, Benjamin JB, Gmitro AF, Krupinski EA, Schwartz SA, et al. Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology. Skelet Radiol. 2008;37(0364–2348 (Print)):423–431. doi: 10.1007/s00256-008-0446-3.
    1. Baker K, Grainger A, Niu J, Clancy M, Guermazi A, Crema M, et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis. 2010;69(10):1779–1783. doi: 10.1136/ard.2009.121426.
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. AnnRheumDis. 1957;16(0003–4967 (Print)):494–502.
    1. Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord. 2010;11(1471–2474 (Electronic)):125. doi: 10.1186/1471-2474-11-125.
    1. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004;50(0004–3591):2471–2478. doi: 10.1002/art.20332.
    1. Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis. 2006;65(0003–4967 (Print)):871–877.
    1. Chmielewski TL, Trumble TN, Joseph AM, Shuster J, Indelicato PA, Moser MW, et al. Urinary CTX-II concentrations are elevated and associated with knee pain and function in subjects with ACL reconstruction. Osteoarthr Cartil. 2012;20(11):1294–1301. doi: 10.1016/j.joca.2012.07.014.
    1. Ishijima M, Watari T, Naito K, Kaneko H, Futami I, Yoshimura-Ishida K, et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011;13(1):R22. doi: 10.1186/ar3246.
    1. Kwoh CK, Roemer FW, Hannon MJ, Moore CE, Jakicic JM, Guermazi A, et al. Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial. Arthritis Rheumatol (Hoboken, NJ) 2014;66(4):930–939. doi: 10.1002/art.38314.
    1. Kraus Virginia Byers, Collins Jamie E, Hargrove David, Losina Elena, Nevitt Michael, Katz Jeffrey N, Wang Susanne X, Sandell Linda J, Hoffmann Steven C, Hunter David J. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Annals of the Rheumatic Diseases. 2016;76(1):186–195. doi: 10.1136/annrheumdis-2016-209252.
    1. Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand M-P, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis. 2006;65(3):360–365. doi: 10.1136/ard.2005.040642.
    1. van Spil WE, Drossaers-Bakker KW, Lafeber FP. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013;72(1468–2060 (Electronic)):29–36. doi: 10.1136/annrheumdis-2011-201177.
    1. Bay-Jensen AC, Tabassi NC, Sondergaard LV, Andersen TL, Dagnaes-Hansen F, Garnero P, et al. The response to estrogen deprivation on cartilage collagen degradation markers; CTX-II is unique compared to other markers of collagen turnover. Arthritis Res Ther. 2009;11(1478–6362 (Electronic)):R9. doi: 10.1186/ar2596.
    1. van Spil WE, Nair SC, Kinds MB, Emans PJ, Hilberdink WKHA, Welsing PMJ, et al. Systemic biochemical markers of joint metabolism and inflammation in relation to radiographic parameters and pain of the knee: data from CHECK, a cohort of early-osteoarthritis subjects. Osteoarthr Cartil. 2015;23(1):48–56. doi: 10.1016/j.joca.2014.09.003.
    1. Karsdal M.A., Byrjalsen I., Alexandersen P., Bihlet A., Andersen J.R., Riis B.J., Bay-Jensen A.C., Christiansen C. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis and Cartilage. 2015;23(4):532–543. doi: 10.1016/j.joca.2014.12.019.
    1. Riddle DL, Stratford PW. Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function. Rheumatol (United Kingdom) 2013;52(12):2229–2237.
    1. Marmon AR, Zeni JA, Snyder-Mackler L. Perception and presentation of function in patients with unilateral versus bilateral knee osteoarthritis. Arthritis Care Res (Hoboken) 2013;65(3):406–413. doi: 10.1002/acr.21825.
    1. Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthr Cartil. 2008;16(5):615–623. doi: 10.1016/j.joca.2007.09.006.
    1. Deveza Leticia A., Kraus Virginia B., Collins Jamie E., Guermazi Ali, Roemer Frank W., Bowes Michael, Nevitt Michael C., Ladel Christoph, Hunter David J. Association Between Biochemical Markers of Bone Turnover and Bone Changes on Imaging: Data From the Osteoarthritis Initiative. Arthritis Care & Research. 2017;69(8):1179–1191. doi: 10.1002/acr.23121.
    1. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60(0003–4967):619–626. doi: 10.1136/ard.60.6.619.
    1. Joseph GB, Nevitt MC, McCulloch CE, Neumann J, Lynch JA, Heilmeier U, et al. Associations between molecular biomarkers and MR-based cartilage composition and knee joint morphology: data from the osteoarthritis initiative. Osteoarthr Cartil. 2018;26(8):1070–1077. doi: 10.1016/j.joca.2018.04.019.
    1. Jørgensen NR, Møllehave LT, Hansen YBL, Quardon N, Lylloff L, Linneberg A. Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population. Osteoporos Int. 2017;28(7):2103–2113. doi: 10.1007/s00198-017-4026-z.
    1. Power JD, Perruccio AV, Gandhi R, Veillette C, Davey JR, Syed K, et al. Neuropathic pain in end-stage hip and knee osteoarthritis: differential associations with patient-reported pain at rest and pain on activity. Osteoarthr Cartil. 2018;26(3):363–369. doi: 10.1016/j.joca.2018.01.002.
    1. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Min Res. 2001;16(0884–0431):1739–1746. doi: 10.1359/jbmr.2001.16.10.1739.
    1. Eastell Richard, Christiansen Claus, Grauer Andreas, Kutilek Stepan, Libanati Cesar, McClung Michael R, Reid Ian R, Resch Heinrich, Siris Ethel, Uebelhart Daniel, Wang Andrea, Weryha Georges, Cummings Steve R. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 2011;26(3):530–537. doi: 10.1002/jbmr.251.

Source: PubMed

3
Sottoscrivi